Myriad Corporate Presentation
Myriad Annual Report 2018

News Releases | Subscribe

May 26, 2020

Cerecor and Myriad Genetics Announce that Levels of Novel Cytokine, LIGHT Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study

Patients hospitalized with COVID-19 had significantly elevated levels of the inflammatory cytokine LIGHT LIGHT was strongly linked with mortality (82%) in patients over 60 years of age Decreasing LIGHT levels using CERC-002 (anti-LIGHT mAb) may prevent cytokine storm induced severe ARDS and thereby

Read More

May 20, 2020

Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer

SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the BRACAnalysis CDx ®   test for use as a companion diagnostic by healthcare

Read More

May 11, 2020

Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer

SALT LAKE CITY, May 11, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the myChoice CDx ®  test for use as a companion diagnostic by healthcare

Read More

May 5, 2020

Myriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results

Total Third-Quarter Revenues of $164.0 Million Third-Quarter Diluted EPS of ($1.55) and Adjusted EPS of ($0.08) SALT LAKE CITY, May 05, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today

Read More

April 28, 2020

Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020

SALT LAKE CITY, April 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal third-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

April 8, 2020

Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic

SALT LAKE CITY, April 08, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, announced today that due to the impact of the global COVID-19 pandemic, the company is withdrawing its fiscal year 2020 financial guidance.

Read More

April 28, 2020

Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020

SALT LAKE CITY, April 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal third-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

March 23, 2020

Myriad Announces Board of Directors Leadership Transition

S. Louise Phanstiel Appointed Chair of the Board of Directors;  John T. Henderson, M.D., to Remain on the Board SALT LAKE CITY, March 23, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today that S.

Read More

February 12, 2020

Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference

SALT LAKE CITY, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that R. Bryan Riggsbee, president and CEO, is scheduled to present at the SVB Leerink Global Healthcare Conference at 10:30 a.m.

Read More

May 26, 2020

Cerecor and Myriad Genetics Announce that Levels of Novel Cytokine, LIGHT Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study

Patients hospitalized with COVID-19 had significantly elevated levels of the inflammatory cytokine LIGHT LIGHT was strongly linked with mortality (82%) in patients over 60 years of age Decreasing LIGHT levels using CERC-002 (anti-LIGHT mAb) may prevent cytokine storm induced severe ARDS and thereby

Read More

May 20, 2020

Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer

SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the BRACAnalysis CDx ®   test for use as a companion diagnostic by healthcare

Read More

May 11, 2020

Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer

SALT LAKE CITY, May 11, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the myChoice CDx ®  test for use as a companion diagnostic by healthcare

Read More

May 26, 2020

Cerecor and Myriad Genetics Announce that Levels of Novel Cytokine, LIGHT Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study

Patients hospitalized with COVID-19 had significantly elevated levels of the inflammatory cytokine LIGHT LIGHT was strongly linked with mortality (82%) in patients over 60 years of age Decreasing LIGHT levels using CERC-002 (anti-LIGHT mAb) may prevent cytokine storm induced severe ARDS and thereby

Read More

May 20, 2020

Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer

SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the BRACAnalysis CDx ®   test for use as a companion diagnostic by healthcare

Read More

May 11, 2020

Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer

SALT LAKE CITY, May 11, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the myChoice CDx ®  test for use as a companion diagnostic by healthcare

Read More